Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 13, Issue 8, Pages 889-899
Publisher
Future Medicine Ltd
Online
2012-06-07
DOI
10.2217/pgs.12.68
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
- (2010) E Martinez-Balibrea et al. BRITISH JOURNAL OF CANCER
- Molecular predictive and prognostic markers in colon cancer
- (2010) Thomas Winder et al. CANCER TREATMENT REVIEWS
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
- (2010) Zhe-Yi Hu et al. EUROPEAN JOURNAL OF CANCER
- Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
- (2010) Howard L. McLeod et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- The UGT1A1*28 Genotype and the Toxicity of Low-Dose Irinotecan in Patients With Advanced Lung Cancer
- (2010) Tomohide Sugiyama et al. ONCOLOGY RESEARCH
- Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
- (2010) B Glimelius et al. PHARMACOGENOMICS JOURNAL
- Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer
- (2009) Heather Taffet Gold et al. CANCER
- Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
- (2009) GENETICS IN MEDICINE
- Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
- (2009) Glenn E Palomaki et al. GENETICS IN MEDICINE
- UGT1A and Irinotecan Toxicity: Keeping It in the Family
- (2009) Janelle M. Hoskins et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
- (2009) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing Tumor Response to Therapy
- (2009) W. A. Weber JOURNAL OF NUCLEAR MEDICINE
- Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers
- (2009) Masashi Takano et al. ONCOLOGY
- UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
- (2009) Christoph Schulz et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
- (2008) D M Kweekel et al. BRITISH JOURNAL OF CANCER
- UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
- (2008) Chun-Yu Liu et al. CANCER
- Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics
- (2008) John F. Deeken et al. CANCER
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
- (2008) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost–effectiveness ofUGT1A1genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
- (2008) Marko Obradovic et al. PHARMACOGENOMICS
- Methodological quality of pharmacogenetic studies: Issues of concern
- (2008) Andrea L. Jorgensen et al. STATISTICS IN MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started